NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Trial of JYB1904 in Patients With Allergic Asthma

CompletedPhase 2

Sponsor: Jemincare

Conditions: Allergic Asthma

Interventions: JYB1904, Omalizumab

Countries: China

This phase IIa trial is meant to evaluate the pharmacokinetics, pharmacodynamics and safety of JYB1904 in patients with allergic asthma.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Able to provide written informed consent voluntarily;
* Aged 18-75 years, weight ≥ 40 kg, male or female;
* Diagnosed Allergic asthma.

Exclusion Criteria:

* Prior exposure to anti-IgE therapy within 1 year;
* Allergic to anti-IgE biologics;
* Current smokers, or quit smoking within 1 year;
* Combined with other non-allergic diseases that cause IgE elevation；
* History of malignancy, autoimmune diseases, Immune complex mediated diseases, Hypereosinophilic syndrome;
* Other conditions unsuitable for the trial judged by the investigator.

Locations (1)

Shanghai, Shanghai Municipality, China